GPX4 and head and neck squamous cell carcinoma: Recently, Allevato et al. [20] performed a genome-wide CRISPR screen of HNSCC to define mechanisms of resistance to glutamine inhibition and found that GPX4 inhibition via RSL3 sensitized cells to glutamine antagonists or inhibitors (DON) in vitro and in vivo, highlighting the synthetic lethality between glutaminase inhibition with GPX4 inhibition as a promising therapeutic strategy for HNSCC.